USA – FDA seeks to improve on EUA processes, inspections following PREPP review

The US Food and Drug Administration (FDA) on Friday said it will work to improve on five areas of its COVID-19 pandemic response to make the agency more resilient in the current and future public health emergencies.

“As we continue our COVID-19 response, it is critical that we learn from both our successes and the challenges we experienced, to best improve our operations,” said Acting FDA Commissioner Janet Woodcock.

The five areas cover FDA’s emergency use authorization (EUA) processes, transparency, public communications, inspection capabilities and supply chain oversight. FDA selected these issues from among the many recommendations laid out in the summary report from its Pandemic Recovery and Preparedness Plan (PREPP) initiative. (RELATED: PREPP initiative: FDA’s COVID-19 response and the path forward, Regulatory Focus 15 January 2021)…